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0022-2836/$ - see front matter © 2009 EThe aggregation process of wild-type human lysozyme at pH3.0 and 60 °C
has been analyzed by characterizing a series of distinct species formed on the
aggregation pathway, specifically the amyloidogenic monomeric precursor
protein, the oligomeric soluble prefibrillar aggregates, and themature fibrils.
Particular attention has been focused on the analysis of the structural
properties of the oligomeric species, since recent studies have shown that the
oligomers formed by lysozyme prior to the appearance of mature amyloid
fibrils are toxic to cells. Here, soluble oligomers of human lysozyme have
been analyzed by a range of techniques including binding to fluorescent
probes such as thioflavin T and 1-anilino-naphthalene-8-sulfonate, Fourier
transform infrared spectroscopy, and controlled proteolysis. Oligomerswere
isolated after 5 days of incubation of the protein and appear as spherical
particles with a diameter of 8–17 nm when observed by transmission
electronmicroscopy. Unlike themonomeric protein, oligomers have solvent-
exposed hydrophobic patches able to bind the fluorescent probe 1-anilino-
naphthalene-8-sulfonate. Fourier transform infrared spectroscopy spectra of
oligomers are indicative of misfolded species when compared tomonomeric
lysozyme, with a prevalence of random structure but with significant
elements of the β-sheet structure that is characteristic of the mature fibrils.
Moreover, the oligomeric lysozyme aggregates were found to be more
susceptible to proteolysis with pepsin than both the monomeric protein and
the mature fibrils, indicating further their less organized structure. In
summary, this study shows that the soluble lysozyme oligomers are locally
unfolded species that are present at low concentration during the initial
phases of aggregation. The nonnative conformational features of the
lysozyme molecules of which they are composed are likely to be the factors
that confer on them the ability to interact inappropriately with a variety of
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Several lines of evidence have recently suggested
that prefibrillar protein aggregates formed prior to
the appearance of mature fibrils are likely to
represent the most toxic entities responsible for cell
dysfunction and death in at least some forms of
amyloid disease.1,2 In particular, nonfibrillar aggre-
gates from several amyloid-forming pathological
and nonpathological proteins have been shown to bed.
18 Structutre of Lysozyme Oligomerstoxic to cultured fibroblasts and pheochromocytoma
cells.3,4 The pathological importance of the soluble
amyloid oligomers is, however, very challenging
to assess since they are difficult to extract from the
brain and other types of tissue. Moreover, a detailed
analysis of the structure of the oligomers at the
molecular level, and of the mechanism of their
formation, is difficult because these species are often
unstable and can exist in dynamic equilibrium with
monomers, oligomers of different sizes, and higher
molecular weight aggregates including fibrils.5
A form of systemic nonneuropathic amyloidosis is
associated with the deposition in various organs of
amyloid fibrils formed by single point mutational
variants of human lysozyme, namely, I56T, F57I,
W64R, and D67H6–8 and two variants with double
mutations F57I/T70NandW112R/T70N.8,9 Recently,
evidence that prefibrillar aggregates formed in vitro
from wild-type hen and horse lysozyme are toxic to
cell cultures has emerged, causing an increase in
membrane permeability and a disruption in the
regulation of Ca2+ ions10 and, ultimately, cell death
in a range of cell lines.11,12 Moreover, injection of such
oligomeric species into rat brains leads to neurode-
generation, whereas mature amyloid fibrils are less
damaging or nontoxic.13
In the present study, the aggregation process of
wild-type human lysozyme has been investigated,
with the particular aim of providing details of the
structure of the species formed early during the
aggregation process. In a previous study, it was
shown by a combined approach of limited proteolysis
and Fourier transform infrared spectroscopy (FTIR)
that the core region of mature fibrils from human
lysozyme produced in vitro at low pH is primarily
formed by residues 32–108 in the 130-polypeptide
chain of the protein and that the rest of the chain is
relatively unstructured.14 The segment 32–108 corre-
sponds to the region found to undergo cooperative
local unfolding in the amyloidogenic variants I56Tand
D67H of human lysozyme15,16 and to be amyloido-
genic in the homologous hen lysozyme.17,18 Given the
high stability of wild-type human lysozyme,19–21
conditions such as low pH and high temperature or
ethanol have been previously used to populate a
partially unfolded state that is prone to form
fibrils.14,22,23 However, these conditions known so far
for the efficient formation of amyloid fibrils by human
lysozyme were found not to be appropriate for this
work because they either induce the fragmentation of
theprotein14,18 or lead to an aggregationprocess that is
too fast to allow isolation of oligomeric species.14
In this work, soluble spherical lysozyme oligo-
mers were identified and then isolated by ultrafil-
tration during the long lag phase of aggregation
under partially denaturing but relatively mild
conditions (pH3.0, 60 °C). The conformational
features of these species have then been investigated
by various techniques including transmission elec-
tron microscopy (TEM), binding to the fluorescent
probes thioflavin T (ThT) and 1-anilino-naphtha-
lene-8-sulfonate (ANS), FTIR, and controlled pro-
teolysis. The results show that prefibrillar lysozymeaggregates have distinctive features when com-
pared with both the monomeric protein and the
mature fibrils. In particular, the FTIR data show that
the α/β-structure characteristic of native lysozyme
undergoes partial unfolding on conversion into the
oligomers, although a significant degree of β-
structure forms and stabilizes the protein aggre-
gates. Moreover, complete digestion of the lysozyme
molecules present within the oligomers indicates
that the polypeptide chain of lysozyme in the
oligomers is locally more unfolded compared to
both the monomeric protein and the final fibrils.
We suggest that the misfolded structure and the
marked hydrophobic character of the oligomers
deduced by ANS experiments can lead to a gain of
toxicity following aggregation of an otherwise
innocuous protein, as it indicates that the surface
of these soluble aggregates is likely to have a high
propensity to interact inappropriately with cellular
components, notably membranes, and, hence, cause
cellular damage and, ultimately, cell death.1,3
Isolation of prefibrillar aggregates of
human lysozyme
The ability of human lysozyme to aggregate into
amyloid fibrils generally increases under conditions
that favor the formation of partially unfolded
species.24,25 In order to identify suitable conditions
for populating oligomeric species in significant
amounts and on a time scale allowing their detailed
characterization, we monitored the thermal unfold-
ing of lysozyme at pH3.0 by far-UV circular dichro-
ism (CD) andANS fluorescencemeasurements (Fig. 1).
A plot of the apparent fraction of folded protein as a
function of temperature increase was derived from
the values of ellipticity at 222 nm recorded during
thermal denaturation experiments (Fig. 1). At pH3.0,
the thermal unfolding follows an apparent two-state
process, as already reported,19 with a temperature of
midtransition (Tm) of 79 °C. The unfolding process of
lysozyme was also followed by monitoring the
fluorescence emission at 475 nm of ANS, a dye
whosewavelength ofmaximumemission shifts from
514 to 475 nm upon binding to exposed hydrophobic
patches.29 Interestingly, the ANS emission intensity
at 475 nm starts increasing at 50 °C and reaches its
maximum value at 76 °C, after which it rapidly
decreases (Fig. 1). This result reveals that partially
unfolded species are populated in a range of
temperature from 50 to 95 °C, with a maximum
population in close proximity to the temperature of
midtransition determined by far-UV CD.
On the basis of these results, the experiments
designed to probe the aggregation of lysozyme were
conducted at pH3.0 and 60 °C. Under these condi-
tions, an ensemble of partially unfolded species able
to bind ANS is significantly populated, correspond-
ing approximately to 22% of the population present
at the temperature of midtransition. Using higher
temperature values for the aggregation experiments
was avoided because even though it would have
allowed the formation of a higher proportion of
19Structutre of Lysozyme Oligomerspartially unfolded lysozyme molecules, it would also
have increased the extent of acid-catalyzed hydrolysis
of the polypeptide chain, mainly at Asp–X peptideFig. 1. Thermal denaturation curves of wild-type
human lysozyme at pH3.0 followed by far-UV CD and
ANS fluorescence. Filled and open circles represent,
respectively, the apparent fraction of folded protein
obtained from the ellipticity value at 222 nm and the
fluorescence emission at 475 nm of ANS during thermal
denaturation (20–95 °C) of human lysozyme in 20 mM
glycine·HCl, pH3.0. The apparent fraction of folded
protein fapp was calculated from the ellipticity at 222 nm
versus temperature curve using the equation fapp=([θ]U−
[θ])/([θ]U− [θ]N), where [θ] represents the observed mean
residue ellipticity under the given conditions and [θ]N and
[θ]U are the corresponding ellipticity values in the native
(N) and unfolded (U) states, respectively. The mean
residue ellipticity [θ] (deg·cm2·dmol−1) was calculated
using the formula [θ]= (θobs/10)·(MRW/lc), where θobs is
the observed ellipticity in degrees, MRW is the mean
residue molecular weight, l is the path length in
centimeters, and c is the protein concentration in grams
per milliliter. The [θ]N and [θ]U values in the transition
region were obtained by linear extrapolation of the
ellipticity values observed in the temperature regions
before and after the transition. Far-UV CD spectra were
obtained with a Jasco J-710 (Tokyo, Japan) dichrograph,
equipped with a thermostated cell holder. The instrument
was calibrated with d-(+)10-camphorsulfonic acid. Tem-
perature-controlled cells of 1-mm path length and a
protein concentration of 7 μM were used for the far-UV
CD measurements. ANS fluorescence emission was
measured for 72-μM solutions of ANS in the presence of
a 2.4-μM concentration of protein in 20 mM glycine·HCl,
pH3.0. The excitation wavelength was fixed at 350 nm and
the fluorescence emission was collected at 475 nm using
excitation and emission slits of 5 nm, and the fluorescence
signal of ANS in the absence of protein was subtracted
from the one recorded in the presence of protein.
Fluorescence emission measurements were conducted
with a Perkin Elmer model LS-50B spectrofluorimeter
(Norwalk, CT, USA), utilizing a 2-mm×10-mm path
length cuvette. Protein concentrations were determined
by absorption measurements at 280 nm on a double-beam
Lambda-20 spectrophotometer from Perkin Elmer. The
extinction coefficient (ɛ) at 280 nm for lysozyme, evaluated
on the basis of its amino acid composition,26,27 was
36,940 cm−1 M−1, whereas the ɛ at 350 nm of ANS was
4950 cm−1 M−1.28bonds.18,30 At pH3.0 and 60 °C, moreover, the
aggregation process is sufficiently slow to allow the
isolation of distinct species along the pathway. In
particular, after 5 days of incubation of the protein
under the conditions described, TEM images show
the presence of a large number of spherical protein
aggregates with diameters ranging from 8 to 17 nm
(Fig. 2, top). The morphology and size are in accord
with the appearance of prefibrillar aggregates
reported for hen lysozyme12,13 and indeed for other
proteins.32–34 The approximate number of lysozyme
molecules in each spherical aggregate can be esti-
mated by counting the number of spheres with the
diameter of the protein (4.5 nm) that can be fitted into
spheres of the size of those observed by TEM, having
diameters between 8 and 17 nm.35 Following this
approximation, lysozyme soluble oligomerswould be
constituted by ∼5–40 protein monomers and would
have a molecular mass in the range of 74–590 kDa.
This number is similar to that defined in recent studies
of other fibrils such as those formed by the SH3
domain of phosphoinositol-3-kinase.36 After 9 days of
incubation, the oligomers are still present in the
solution, as assessed by TEM: however, a number of
them can be seen to be interacting with each other to
form elongated structures. After 15 days of incuba-
tion, mature amyloid-like fibrils with a 9- to 14-nm
diameter are evident in the micrographs (Fig. 2, top).
These findings are consistent with a situation in
which, during the course of the incubation process,
the initially formed oligomers physically associate
with each other, giving rise to filamentous structures
that subsequently convert into mature fibrils.
In order to provide structural details about the
early aggregates of lysozyme, we devised a method
that was able to separate them from the monomeric
protein. FTIR and CD spectra of nonpurified
oligomer-containing samples (i.e., samples incu-
bated under the conditions used here for 5 days)
are nearly identical with those of the monomeric
protein before incubation, where no aggregates are
visible by TEM. This finding is probably due to the
low concentration of soluble aggregates in the
solution even after 5 days of incubation, such that
the signals arising from the monomeric protein
essentially overwhelm those coming from the
oligomers. Ultracentrifugation of the solution at
380,000g did not lead to the formation of any pellet,
however, indicating that the lysozyme oligomers are
highly soluble; indeed, the definition of soluble
amyloid oligomers is based on their continued
presence in the supernatant after very high speed
centrifugation (N370,000g).37,38 By contrast, mature
fibrils are spun down after centrifugation at
b100,000g;39 thus, the ultracentrifugation of a
lysozyme sample incubated at pH3.0 and 60 °C for
9 days, in which both oligomers and fibrils are
present as indicated by TEM, leads to the partition-
ing of spherical aggregates in the supernatant and of
fibrils in the pellet.
In the light of these results, lysozyme oligomers
were isolated by ultrafiltration of samples after
5 days of incubation, which do not contain fibrils,
Fig. 2. Aggregation of human lysozyme at pH3.0 and 60 °C monitored by (top) TEM and (bottom) ThT and ANS
binding assays. Lysozyme was dissolved in 20 mM glycine·HCl, pH3.0, at a 0.65 mM (9 mg/ml) concentration in order
to induce the formation of protein aggregates. The solution was filtered with a 20-nm pore-size filter (Whatman,
Maidstone, UK) and then incubated at 60 °C. TEM pictures were taken on a Tecnai G2 12 Twin instrument (FEI
Company, Hillsboro, OR, USA), operating at an excitation voltage of 100 kV. Samples for TEM were diluted 10 times,
and a drop of the solution was placed on a Butvar-coated copper grid (400-square mesh) (TAAB Laboratories
Equipment Ltd., Berks, UK), followed by a drop of uranyl acetate solution (1%, w/v). For the ThT assay, aliquots (5 μl)
of the protein solution, incubated for the periods of time indicated, were added to 25-mM solutions (496 μl) of ThT in
25 mM phosphate buffer (pH6.0). The excitation wavelength was fixed at 440 nm, and the fluorescence emission was
collected at 485 nm (triangles). The maximum fluorescence value of ThT has been normalized to 100. For the ANS
assay, aliquots from the solution in which aggregation was taking place were diluted with 20 mM glycine·HCl, pH3.0,
and ANS was added to a molar ratio of protein:ANS of 1:2. The excitation wavelength was fixed at 350 nm and the
fluorescence emission was collected at 475 nm at room temperature (circles). The maximum fluorescence intensity
values of ANS have been normalized to 100. Open circles represent the fluorescence emission of ANS in the presence
of the various aliquots, and filled circles represent that of the supernatants of the same aliquots obtained after
ultracentrifugation for 90 min at 4 °C at 90,000 rpm (380,000g) in a Beckman-Coulter MLA-130 ultracentrifuge (model
Optima MAX-E, Palo Alto, CA). (Bottom, inset) SDS-PAGE analysis of standard human lysozyme (lane 1), of a 15-day
aggregated lysozyme sample (lane 2), of the supernatant (lane 3), and of the pellet (lane 4) obtained after
ultracentrifugation of a similar aggregated sample. SDS-PAGE was performed on 4–12% precast Bis–Tris NuPAGE gels
(Invitrogen, Carlsbad, CA, USA) in 4-morpholineethanesulfonic acid buffer, under reducing conditions. Before SDS-
PAGE analysis, samples containing fibrils were dissolved in 95% dimethyl sulfoxide.31 The same amount of protein
(5 μg) was loaded in each well. A molecular weight standard was loaded onto the gel and the position of the relative
bands is reported on the right.
20 Structutre of Lysozyme Oligomersthrough 100-kDa cutoff ultrafilters. The amount of
lysozyme in the retentate was ∼5% of the total
starting material, as estimated by UV absorption
measurements, confirming that lysozyme oligomers
are not highly populated species. In these samples,
the material collected on a 100-kDa filter and
observed by TEMwas composed of spherical species
with an 8- to 17-nm diameter, similar to those
observed in samples prior to centrifugation orultrafiltration, indicating that the purification pro-
cess does not affect the nature of the oligomers.
Characterization of lysozyme oligomers
The structural features of soluble lysozyme aggre-
gates have been investigated by a range of techniques,
including ANS and ThT binding fluorescence, FTIR,
and proteolysis experiments.
21Structutre of Lysozyme OligomersThe fluorescence assay with ThT is indicative of
the presence of ordered β-sheet structure in amyloid
aggregates,40 and the kinetics of lysozyme fibril
formation were monitored by following the increase
of ThT fluorescence emission intensity during the
aggregation process (Fig. 2, bottom, triangles). The
experimental data points fit well to a sigmoidal
curve, indicating the presence of an initial lag phase
of about 10 days, followed by a rapid growth phase
that reaches a plateau at 15 days. TEM pictures show
that after 15 days of incubation, fibrils with typical
amyloid morphology are present in the sample (Fig.
2, top). These fibrils were separated from nonag-
gregated soluble material by ultracentrifugation; ca
90% of the total lysozyme content present in the
initial solution was found in the pellet, as assessed
by UV absorption measurements, indicating that
almost all protein molecules had aggregated into
fibrils. SDS-PAGE analysis of a 15-day sample was
then performed in order to check the chemicalintegrity of the protein (Fig. 2, bottom, inset).
Monomeric human lysozyme prior to incubation
(lane 1), a 15-day-incubated sample (lane 2), and an
aliquot from an ultracentrifuged pellet of the latter
(lane 4) and from its supernatant (lane 3) all migrate
in a similar manner (Fig. 2, bottom, inset), indicating
that no hydrolysis had occurred and that the protein
molecules within the aggregates or present in
solutions in which aggregation had occurred are
all full-length lysozyme.
Lysozyme aggregation has also been followed by
monitoring the degree of ANS binding, recording
the increase in the fluorescence emission at 475 nm
of ANS added to aliquots withdrawn from the
aggregation mixture at different time points (Fig. 2,
bottom, open circles). The experimental data points
do not fit to a sigmoidal curve but show an initial
increase during the previously detected lag phase, a
sudden increase corresponding to the growth phase
observed in the ThT fluorescence experiment, and
then a plateau region at about 15 days. In order to
distinguish whether the ANS fluorescence was due
to the soluble oligomers or to the amyloid fibrils
present in solution, we ultracentrifuged aliquotsFig. 3. FTIR spectra of (a) monomeric lysozyme
dissolved in 20 mM glycine·DCl, pH⁎3.0 (uncorrected
for isotopic effects) and (b) lysozyme oligomers produced
after 5 days of incubation of the protein at 60 °C in the
same buffer. (c) The second derivatives of the amide I
bands of lysozyme oligomers (continuous line) and of the
monomeric protein (broken line) were used to identify the
different spectral components. The thin broken line
represents the second derivative of the spectrum of mature
amyloid fibrils obtained previously at low pH.14 Curve
fitting was performed with Gaussian and Lorentzian
lineshapes and with bandwidths varying between 15 and
20 cm−1.42 The heights, widths, and positions of each band
were optimized iteratively.43,44 The sum of the fitted
curves is shown as a broken line, closely overlapping the
experimental trace, shown as a continuous line (a and b).
Deuterated lysozyme was prepared by dissolving the
protein in D2O at pH⁎3.8 at a concentration of 0.68 mM,
filtering the protein solution with a 20-nm pore-size filter
(Whatman) and incubating it at 80 °C for 40 min, followed
by lyophilization.45 The spectrum in (a) was registered
after dissolving the monomeric deuterated protein in
20 mM glycine·DCl, pH⁎3.0, at a 5 mg/ml concentration.
The spectrum in (b) was registered after separating
lysozyme oligomers from the monomeric protein by
filtration with Microcon YM-100 ultrafilters, following
the procedure suggested by the supplier (Millipore,
Bedford, MA, USA). The concentration of the purified
oligomers collected on the filter was 1 mg/ml, as
evaluated by UV absorbance measurement. FTIR spectra
were recorded at 20–22 °C using a Perkin Elmer 1720X
spectrometer (Norwalk), purged with a continuous flow
of N2 gas. Protein samples were placed between a pair of
CaF2 windows separated by a 50-μm Mylar spacer. For
each protein sample, 50 interferograms were accumulated
at a spectral resolution of 2 cm−1. The spectra were
analyzed using the Grams 32 program version 4.14
(Galactic Industries Corporation, Salem, NH). Buffer
spectra were recorded under conditions identical with
those used for protein samples and subtracted from the
spectra of the latter.
Table 1. Secondary-structure content of monomeric and aggregated human lysozyme, as determined by FTIR (see Fig. 3)
Wavenumbera (cm−1) Structural assignment Monomer (%)b Oligomers (%)b Mature fibrils (%)b
1614–1630 Aggregated β-sheet — 17 32
1632 Antiparallel β-sheet 32 — —
1641–1644 Disordered/Loops — 41 47
1649 α-Helix 49 — —
1658 Turns 12 27 14
1666 Turns — 7 —
1674–1676 Antiparallel β-sheet 7 3 —
1688 Aggregated β-sheet — 5 7
a Peak position of the amide I band components, as deduced by the second-derivative spectra.
b Percentage area of the amide I band components, as obtained by integrating the area under each deconvoluted band. The areas
corresponding to side-chain contributions located at 1604–1606 cm−1 have not been considered.
22 Structutre of Lysozyme Oligomersremoved from the reaction mixture at the different
time points, and the ANS binding assay was
repeated for the supernatants, where only protein
monomers and soluble oligomers are present,
thereby excluding any contribution to the fluores-
cence enhancement from fibrils (Fig. 2, bottom, filled
circles). The fluorescence spectrum of ANS in the
presence of the monomeric protein before incuba-
tion, collected at pH3.0 at 20 °C, is identical with
that in the absence of the protein, both in terms of
maximum emission wavelength (510–516 nm) and
intensity, indicating that monomeric lysozyme does
not bind ANS, a result attributable to its existence in
a native-like conformation29 (data not shown). By
contrast, the fluorescence emission at 475 nm of
ANS for the supernatants reveals that even after
2 days of incubation, a stable protein species capable
of binding ANS is present and suggests that the
quantity of this species increases slowly for up to
20 days of incubation. TEM pictures show that after
2 days of incubation, small quantities of spherical
aggregates are present in the samples (not shown).
This result indicates that the lysozyme oligomers
visible by TEM must contain substantial regions of
exposed hydrophobic surface and, therefore, sug-
gests that a major conformational rearrangement
has taken place in the protein during incubation.
Amyloid fibrils formed after 12 days of incubation
bind ANS, as already reported for other systems,
indicating that they also possess nonnative
surfaces.34,41 Since the quantum yield of ANS is
likely to increase considerably with increasing
amyloid aggregate size, the latter suggests that the
binding of ANS to the oligomers could be much
greater than the binding to the fibrils.
The secondary structure of lysozyme when it is in
an oligomer was assessed by FTIR and compared to
that of the protein before incubation (Fig. 3). The
FTIR spectra have been deconvoluted into their
component bands, each of which can be associated
with specific elements of secondary structure.46,47
The FTIR spectrum of the monomeric protein at
pH3.0 is indicative of the characteristic native fold,
with a prevalence of α-helical structure at 1649 cm−1
(49%), of antiparallel β-sheet structure, suggested by
the presence of the two characteristic bands at 1632
and 1674 cm−1 (39%), and of turns giving rise to the
component at 1658 cm−1 (12%)48,49 (Fig. 3a andTable 1). The FTIR spectrum of lysozyme oligomers
formed after 5 days of incubation at pH3.0 and
isolated by ultrafiltration shows substantial changes
when compared to that of the monomer, both in
terms of the positions and intensities of the bands
(Fig. 3b and c). In particular, the main band is shifted
to a lower wavenumber (1644 cm−1, 41%), indicat-
ing that some of the α-helical structure present in the
monomer has been lost as a result of a partial
unfolding of the polypeptide chain. Moreover, two
new bands at 1630 and 1688 cm−1 are evident,
accounting for 22% of the structure, which are
typical of the intermolecular β-sheet structure
present in amyloid fibrils, as the absorption maxima
at ∼1632 and 1674 cm−1, characteristic of antipar-
allel β-sheet structure, shift to 1611–1630 and
∼1684 cm−1, respectively.50 Finally, the FTIR spec-
trum of the oligomers shows that the components at
1658 and 1666 cm−1 characteristic of turns are
substantially increased (34%).
It has been reported previously that the FTIR
spectrum of mature lysozyme fibrils at low pH is
characterized by a large contribution of the bands at
1614 and 1688 cm−1 (32% and 7%, respectively),
corresponding to β-structure, but that the main
contribution is still at 1641 cm−1 (47%), correspond-
ing to random structure, plus a 14% content of turns
indicated by a band at 1658 cm−1.14 Therefore, as the
aggregation process of lysozyme proceeds, the
amount of β-structure in the aggregates increases
even though the entire polypeptide chain does not
become involved in this type of structure.14
A proteolysis experiment with pepsin was also
conducted on the soluble prefibrillar lysozyme
aggregates and on monomeric lysozyme prior to
incubation (Fig. 4). The aim was to gain information
on the structure and dynamics of lysozyme in its
monomeric and aggregated forms, since proteolytic
cleavage generally occurs at flexible regions of a
polypeptide chain that are devoid of hydrogen-
bonded regular secondary structure such as α-
helices and β-strands.52–54 The proteolysis reactions
were conducted at 57 °C, after lowering the pH of
the solution to pH2.0 with aqueous HCl, since, at
this pH, pepsin exhibits its maximum activity.55 The
first peptide bonds cleaved by pepsin in the
polypeptide chain of monomeric lysozyme at
pH2.0 are Phe57–Gln58 and Ala108–Trp109, located
Fig. 4. Susceptibility to proteolysis with pepsin of wild-type human lysozyme in its monomeric, oligomeric, and
fibrillar states. (a) SDS-PAGE analysis of the proteolysis with pepsin of an oligomer-containing sample formed after 5 days
of incubation of lysozyme at pH3.0 and 60 °C (Oligo) and of monomeric lysozyme (LYS). SDS-PAGE was conducted
under nonreducing conditions.51 The main proteolytic fragments are indicated near the corresponding electrophoretic
bands. Some fragments are nicked species linked by the disulfide bonds of the protein. The proteolysis reactions were
conducted at pH2.0 at 57 °C with enzyme:substrate=1:50 (by weight) of pepsin. Aliquots from the proteolysis mixtures
were withdrawn after 10 and 30 min of incubation, and the reactions were quenched with an equal volume of aqueous
NH3 (1:100, v/v). The identity of the protein fragments separated by reverse-phase HPLC was assessed by electrospray
ionization–mass spectrometry with a Q-Tof Micro mass spectrometer (Micromass, Manchester, UK). (b) Schematic
representation of the secondary structure of human lysozyme48 indicating the proteolytic sites obtained after digestion
with pepsin. The boxes indicate the location along the 130-residue chain of the protein of α-helices (A–D) and of the 310
helical elements (h1–h3), while the arrows represent the three β-strands (S1–S3). The connectivity of the four disulfide
bonds Cys6–Cys128, Cys30–Cys116, Cys65–Cys81, and Cys77–Cys95 of the protein is indicated by continuous lines.
Black and white arrows indicate the pepsin cleavage sites on the monomeric protein and the additional sites of cleavages
on the protein in the prefibrillar form, respectively. Boxed arrows indicate the sites of cleavage of lysozyme in the mature
amyloid fibrils studied previously.14
23Structutre of Lysozyme Oligomersin the native structure in the β-domain and in the 310
helix between helices C and D, respectively, fol-
lowed by the peptide bonds Gly19–Tyr20, Leu25–
Ala26, Leu31–Ala32, and Gln123–Tyr124 (see Table
S1). These results indicate that the regions of the
sequence encompassing these peptide bonds are
unfolded enough, for at least a significant fraction of
time, to allow the attack of the protease molecule
(Fig. 4a and b). Interestingly, the proteolysis of
lysozyme in its oligomeric form leads to the
formation of the same peptic fragments as it does
in the monomeric, partially unfolded state.19,22
Remarkably, however, within the oligomers, lyso-
zyme is digested to a greater extent if compared
with the monomeric state; after 30 min of incuba-
tion, no intact protein is evident in the proteolytic
mixture, and most importantly, the three peptide
bonds Asp53–Tyr54, Leu84–Leu85, and Ala92–
Val93, which are located in the C-helix and the β-
domain, are also cleaved (Fig. 4a and b), while for
the monomeric protein, the degree of degradation at
these peptide bonds is negligible. These results
indicate that the polypeptide chain of lysozyme in
the oligomeric state is more unstructured than that
in the monomeric form, especially in the segments
encompassing the β-domain and the C-helix of the
native protein. In addition, it has previously been
shown that mature amyloid fibrils produced at lowpH experience detectable proteolysis at very few
sites in the sequence, despite the fact that there are
many potential peptic sites distributed along the
chain, indicating that the polypeptide chain of
lysozyme embedded into mature fibrils is arranged
in a largely compact and stable structure (Fig. 4c).14
Furthermore, proteolysis with pepsin of fully
unfolded lysozyme, when the disulfide bonds of
the protein are reduced and alkylated, conducted
under the same conditions, leads to the formation of
short peptides resulting from cleavage all along the
sequence, indicating that if the protein chain is
devoid of any fixed structure (as in this case),56 it is
essentially fully accessible to the protease (data not
shown).
General insights into amyloid disease
The existence of aggregates with toxic activity
formed early on the aggregation pathway of
lysozyme from various species has been shown by
several groups.10–13,57 The aim of the present study
was to obtain detailed structural information about
the early aggregates formed by wild-type human
lysozyme at acidic pH and moderately high
temperature. During the aggregation process, lyso-
zyme forms spherical oligomers that, upon pro-
longed incubation, convert into mature amyloid
24 Structutre of Lysozyme Oligomersfibrils. Much evidence suggests that the former
species could be those with high toxicity. An
important finding of this study is the low concen-
tration in the solution of oligomeric species (∼5%)
under the conditions used here. As it was recently
reported that the extracellular chaperone clusterin is
able to inhibit the aggregation of the amyloidogenic
I56T variant of lysozyme, an observation attributed
to its specific interaction with oligomeric species
formed at low population (less than 5%) during the
lag phase of the aggregation process;57,58 species of
this type are likely to be fundamental for triggering
the aggregation of lysozyme even if present only in
low concentration.
Another remarkable characteristic of the lysozyme
oligomers reported here is the hydrophobicity of
their surfaces, as revealed by their avid binding of
ANS. The exposure of hydrophobic regions able to
bind ANS is also associated with the formation of
soluble early aggregates of lysozyme at pH12.2.59
ANS has similarly been reported to interact with
oligomeric aggregates of other proteins;34 for exam-
ple, well before the formation of amyloid fibrils able
to bind ThT, insulin begins to undergo a series of
structural changes, detected by binding with ANS.41
Crucially, regions of exposed hydrophobicity have
been strongly implicated in the cytotoxicity of
protein aggregates, as it has been proposed that
the pathogenic nature of prefibrillar aggregates
could lie in the exposure of groups that are normally
buried in a folded protein.1,3,60 Interestingly, the
ANS signal arising from oligomeric species of
lysozyme does not decrease over time, it even
slightly increases, despite the fact that the concen-
tration of soluble protein is progressively reduced
and that the equilibrium is shifted toward aggre-
gated species. Indeed, ultrafiltration analysis indi-
cates that, after 5 days, oligomers involve only 5% of
lysozyme molecules in solution, while the rest are in
the monomeric form, yet the overall ANS signal
corresponds to 20% of its maximum value. When the
aggregation process reaches a plateau (15 days), the
ANS signal arising from oligomers (see Fig. 2,
bottom, filled circles) is increased to 30% of the maxi-
mum value. Since ultracentrifugation experiments
show that, at this time,∼90% of the protein molecules
are embedded into fibrils, the latter appear to exist in
equilibrium with ∼7.5% of oligomeric species and
∼2.5% of monomers.
Lysozyme oligomers are digested by pepsin to a
greater extent than is themonomeric protein, suggest-
ing that lysozyme molecules within these species are
more flexible andunfolded. This result is similar to the
findings of a study of the SH3 domain of phosphoi-
nositol-3-kinase, where soluble amyloid precursors
formed at low pH were shown to be completely
degraded by pepsin, although mature amyloid fibrils
remain largely intact under the same conditions.61,62
Moreover, the observation that species formed early
in the aggregation process of the fragment 105–115 of
transthyretin are unstable under high hydrostatic
pressure because they still contain cavities and
packing defects suggests again that they are not yethighly ordered.63 In addition, the proteolysis data for
lysozyme are in accord with the FTIR data reported
here, which show that the initial aggregates possess a
high content of random structure (∼40%) but, at the
same time, have some intermolecular β-structure
(22%). The presence of a significant fraction of random
structure has also been observed by CD measure-
ments in oligomers formed by the amyloid β-
peptide.64 It therefore appears likely that these are
common features of the oligomeric species formed by
different peptides and proteins.
The current model proposed for lysozyme amy-
loid aggregation suggests that intermolecular inter-
actions between those regions that are unfolded in
the amyloidogenic intermediate (i.e., the C-helix and
the β-domain) initiate the process that leads to the
formation of mature amyloid fibrils.15,16 The data
described here indicate that the formation of
lysozyme oligomers also involves the unfolding of
a substantial part of the remainder of the polypep-
tide chain, at least transiently, since the oligomers
are more unstructured and sensitive to proteolysis,
and also expose nonnative cluster of hydrophobic
groups on their surfaces. Moreover, FTIR data
suggest that at least part of this unfolding process
results in the formation of an initial stretch of
intermolecular β-structure, an event that is likely to
promote nonnative interactions elsewhere in the
molecule and, thus, to help stabilize oligomeric
assemblies. Indeed, if the entire region suggested to
be unfolded, corresponding to 45–58% of the
lysozyme sequence,14–16 was already embedded in
the cross-β core of the oligomer, the β-sheet content
of the oligomers would be greater than the 22%
found from the FTIR analysis.
As aggregation proceeds, the lysozyme chain
converts progressively into β-structure; FTIR sug-
gests that the proportion of β-sheet structure
increases from 22% in prefibrillar aggregates to
39% in mature fibrils (see Table 1). The structural
transitions that lead to increasing order in amyloid
proteins have been compared to crystallization
phenomena, and indeed, when polymers approach
crystallinity, they have been observed to pass
through species of increasing order on the way to
their stable end products.65 In the case of lysozyme,
it has previously been demonstrated, by means of
proteolysis experiments, that in mature fibrils, both
the β-domain and the C-helix of the native state are
reorganized prior to incorporation within the β-core
of the fibrils.14 The fact that lysozyme oligomers are
completely and rapidly digested by pepsin, while
mature fibrils are only partially and slowly digested,
indicates that the species formed first during
aggregation are likely to have the flexibility required
for such a process to take place.
Overall, the results presented here shed light on
the elusive conformational features of oligomeric
species formed during the first phases of the
aggregation process that results in peptides and
proteins converting into amyloid fibrils. In the case
of the pathogenic behavior of mutational variants of
lysozyme, the aggregation process is enhanced
25Structutre of Lysozyme Oligomersrelative to the wild-type protein as a result of the
destabilization of the native state.21 In this systemic
disease, the resulting proliferation of fibrils is
undoubtedly the reason that large quantities of
deposits are formed, which cause physical damage
to organs such as the liver.1,66 The toxicity of the
oligomers is, therefore, not necessarily the primary
origin of the disease, although it may well play a
very significant role. In many other cases, however,
the oligomeric intermediates formed during fibril
formation are highly likely to be the primary toxic
agents involved in amyloid disease; this situation is,
for example, probable in both type II diabetes and
neurodegenerative diseases, where cell damage and
cell death are clearly evident. The results of the
present study could have general significance not
only because they reveal the possible generic toxicity
of misfolded protein oligomers but also because
they are a key factor in defining our ability to rise to
the challenge of developing therapeutic agents to
prevent or combat these debilitating and increas-
ingly prevalent conditions. As these conditions
range from systemic deposition disorders to neuro-
degenerative disorders such as Alzheimer's disease
and type II diabetes, this goal is particularly urgent
because of the increasingly dominant role these
diseases now play in the modern world.Acknowledgements
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